about
Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA.HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective.Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adultsHealth care index score and risk of death following tuberculosis diagnosis in HIV-positive patients.Hepatitis C virus (HCV) RNA profiles among chronic HIV/HCV-coinfected individuals in ESPRIT; spontaneous HCV RNA clearance observed in nine individuals.Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study.Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected?Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals.TB meningitis in HIV-positive patients in Europe and Argentina: clinical outcome and factors associated with mortalityIncreased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis.Multi-drug-resistant tuberculosis in HIV positive patients in Eastern Europe.Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients.Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy.Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe.Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study.Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?Hepatitis delta in HIV-infected individuals in Europe.High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study)Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trialAccuracy of diabetes screening methods used for people with tuberculosis, Indonesia, Peru, Romania, South AfricaRisk score for predicting mortality including urine lipoarabinomannan detection in hospital inpatients with HIV-associated tuberculosis in sub-Saharan Africa: Derivation and external validation cohort studyPoint of care HbA1c level for diabetes mellitus management and its accuracy among tuberculosis patients: a study in four countriesWhere are patients missed in the tuberculosis diagnostic cascade? A prospective cohort study in GhanaCOVID-19 in Great Britain: epidemiological and clinical characteristics of the first few hundred (FF100) cases: a descriptive case series and case control analysis
P50
Q33648600-6DC1A8B1-C4C2-40FA-BD17-52B6DB367F91Q34260569-F4DBD4E6-86E1-4A92-A6D3-1BAE0D381C19Q34387456-C1FF154E-872B-4A98-B529-F0670FAD4137Q39485675-B198AEF3-1830-41A1-BE99-3B26D9DAA6CEQ40482468-FD8DD60B-368A-43CD-B76C-ECEF7F51C4F5Q41219108-37B6903F-2491-4F0F-8DD6-A0921B0E69BFQ41332840-10C1D9C3-6A7B-477E-B5BA-443F03CF4D4AQ41336688-531476C2-37BD-4D73-B780-E03712EE8113Q41967770-AF1D1E11-1796-4337-B9EB-FB3F222964F1Q42230942-1F699357-C92A-470A-8096-6B0A223B5769Q42240180-65D49C06-6BD7-468B-AD97-DFC95B504CB2Q42982110-458436F7-7545-4BD6-A358-35536E3BE116Q42990589-A96B3BDA-3163-411A-8173-225CB6570824Q43456031-2F08E946-732C-4382-AA4E-72F1A413FF00Q50119032-6F7AA829-6B31-4D67-B5A9-C37E31CDAB4DQ51070641-1E945CDF-274F-4EDF-9360-C0A750BB2FE6Q54352996-280988C5-5AA3-4F48-A369-F42046631F02Q56911375-8D9B3B4E-D96E-488D-B5C1-0E5729F28DB8Q56931078-4FB3C510-E981-431B-8B23-CC2DE90B843BQ61192511-102529D5-B5B2-42D1-B6A8-7AC9D06503DCQ63379734-77641AF2-AABE-46B3-BF31-7B07129CF3F5Q63379735-A71BFCE6-02C6-47BB-92BD-9806EAEE3A4DQ90459224-D5B36E0E-E655-49EE-9437-FCD4AF0B4172Q95605150-E558196E-9573-4979-AECD-067CD0E8CD7D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Daniel Grint
@ast
Daniel Grint
@en
Daniel Grint
@es
Daniel Grint
@nl
Daniel Grint
@sl
type
label
Daniel Grint
@ast
Daniel Grint
@en
Daniel Grint
@es
Daniel Grint
@nl
Daniel Grint
@sl
prefLabel
Daniel Grint
@ast
Daniel Grint
@en
Daniel Grint
@es
Daniel Grint
@nl
Daniel Grint
@sl
P106
P1153
53982707900
P21
P31
P496
0000-0001-8001-6544